Covered recipient · General Payments record
JUAN P ALDERUCCIO
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$38,831.85
- Reported across 92 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $16,994.50 | 6 |
| Travel and Lodging | $1,034.16 | 3 |
| Food and Beverage | $611.30 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $8,232.00 | 2 |
| ABBVIE INC. | $5,930.51 | 8 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $4,169.66 | 2 |
| Genmab U.S., Inc. | $131.65 | 1 |
| BeiGene USA, Inc. | $128.23 | 1 |
| ADC Therapeutics America, Inc. | $47.91 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $142.55 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103199099 | CMS |
| ABBVIE INC. | $374.51 | 06/02/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104174976 | CMS |
| ABBVIE INC. | $504.20 | 06/03/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104174978 | CMS |
| ABBVIE INC. | $1,087.50 | 07/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103131271 | CMS |
| ABBVIE INC. | $155.45 | 07/01/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104174980 | CMS |
| ABBVIE INC. | $2,900.00 | 07/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103131273 | CMS |
| ABBVIE INC. | $725.00 | 07/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103131275 | CMS |
| ABBVIE INC. | $41.30 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103199101 | CMS |
| ADC Therapeutics America, Inc. | $47.91 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1121185824 | CMS |
| BeiGene USA, Inc. | $128.23 | 12/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120855730 | CMS |
| Genmab U.S., Inc. | $131.65 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126828240 | CMS |
| Novartis Pharmaceuticals Corporation | $119.66 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086746811 | CMS |
| Novartis Pharmaceuticals Corporation | $4,050.00 | 12/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1086746813 | CMS |
| Regeneron Pharmaceuticals, Inc. | $3,528.00 | 01/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1114395890 | CMS |
| Regeneron Pharmaceuticals, Inc. | $4,704.00 | 01/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1114395892 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.